CD274 and neoplasm: The positive predictive synergy between CD20+ TILs and PD-1+ immune cells or PD-L1+ tumour cells revealed by Arias-Pulido et al. (2018) could serve as a springboard to stimulate more large-scale randomised controlled studies to assess the potential use of TIL-Bs as a component of a multi-biomarkers panel for the identification of patients who may benefit from immunotherapy.